XconomyBoston Driven by 20 years in the military, the CEO of Theradaptive hopes his firms regenerative paint technology platform can transform bone repair, spinal fusion, and sports medicine. The Boston-based firm, spun out of MIT, has a computational platform it says turns recombinant proteins into material-binding variants that behave like a paint. This can then be used to coat implants, devices, and injectable carriers to enable long-term local delivery without off-target effects.
As you were browsing http://www.streetinsider.com something about your browser made us think you were a bot. If you are interested in http://www.streetinsider.com content, APIs are available. Please contact us here http://www.streetinsider.com/signup_content.php After completing the CAPTCHA below, you will immediately regain access to http://www.streetinsider.com
PRINCETON, N.J. & ALAMEDA, Calif.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and Exelixis, Inc. (NASDAQ: EXEL) today announced that CheckMate -9ER, a pivotal Phase 3 trial evaluating Opdivo (nivolumab) in combination with CABOMETYX(cabozantinib) compared to sunitinib in previously untreated advanced or metastatic renal cell carcinoma (RCC), met its primary endpoint of progression-free survival (PFS) at final analysis, as well as the secondary endpoints of overall survival (OS) at a pre-specified interim analysis, and objective response rate (ORR)
"Viral vector manufacturing has transitioned from a niche industry to the cornerstone of the future of biopharmaceuticals," said Udit Batra, member of the Merck Executive Board and CEO, Life Science. "Few companies have the scale and quality systems in place for manufacturing commercial viral vector products.
Leading Urology KOLs Host Live Webinar Entitled The Protect PNS for OAB: A Wireless Uro-Stimulation Injectable Technology on April 29 at 5pm ET Yahoo Finance
CLEVELAND--(BUSINESS WIRE)-- Athersys, Inc. (NASDAQ: ATHX) announced today that the U.S. Food and Drug Administration (FDA) has authorized the Company to initiate a Phase 2/3 pivotal study to assess the safety and efficacy of MultiStem therapy in subjects with moderate to severe acute respiratory distress syndrome (ARDS) induced by the novel coronavirus disease (COVID-19).
People who develop Parkinson's disease at a younger age (before age 50) may have malfunctioning brain cells at birth, according to a study that also identified a drug that may help these patients. At least 500 000 people in the United States are diagnosed with Parkinson's each year
- The expanded strategic collaboration includes the use of Celularity's proprietary CYNK-001 for treatment of SARS-CoV-2 virus, which causes COVID-19 and Acute Respiratory Distress Syndrome WARREN, N.J., April 9, 2020 /PRNewswire/ --Celularity Inc. ("Celularity" or the "Company"), a clinical-stage company developing allogeneic cellular therapies from human placentas, today announced the expansion of its existing collaborative license agreement with United Therapeutics Corporation's (Nasdaq: UTHR) wholly-owned subsidiary, Lung Biotechnology PBC, to include the treatment of COVID-19 and Acute Respiratory Distress Syndrome (ARDS)
ANKARA Apheresis therapy can be widely beneficial in treating patients with the novel coronavirus, the president of the World Apheresis Association said Wednesday. Speaking on convalescent plasma therapy, Fevzi Altuntas said this therapy is being successfully applied in many scientific areas of therapeutic apheresis in Turkey. What is apheresis
About STEMCELL Technologies STEMCELL Technologies is Canadas largest biotechnology company, with over 1,500 employees and year-on-year growth of approximately 20% for the last 26 years. Based in Vancouver, STEMCELL supports life sciences research around the world with more than 2,500 specialized reagents, tools, and services
Recent Comments